DelveInsight’s “Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Blastic Plasmacytoid Dendritic Cell Neoplasm market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Blastic Plasmacytoid Dendritic Cell Neoplasm drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Blastic Plasmacytoid Dendritic Cell Neoplasm treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An Overview
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy of the bone marrow and blood that can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. In fact, skin lesions are present in most patients with BPDCN. These skin lesions are often a deep purple color, and patients often develop multiple lesions. More men than women are diagnosed with BPDCN (~3:1 ratio), and it is most common in patients aged 60 years and older. Although BPDCN occurs more frequently in the elderly, the tumor may occur in patients of any age, including pediatric patients.
Previously referred to as blastic NK cell leukemia and agranular CD4+/CD56+ hematodermic neoplasm, BPDCN was officially named by the World Health Organization in 2008. BPDCN can also evolve from prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), so patients with those diseases and skin lesions should be specifically evaluated for BPDCN.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Key Facts
-
According to a study by Petrella T et al., titled, “Blastic NK-cell lymphomas (agranular CD4 + CD56 + hematodermic neoplasms): a review”, BPDCN has been described in all age groups but is most common in adults. BPDCN represents 0.7 percent of primary cutaneous skin lymphomas.
-
As per a study published by Aurelia Meloni et al., titled, “Review on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with data on clinics, and the genes involved”, the incidence of this neoplasm accounts for 0.4% of all hematologic neoplasms, 0.7% of the primary cutaneous lymphomas, and less than 1% of all acute leukemias (Facchetti et al., 2008; Riaz et al., 2014; Rossi et al., 2006; Pagano et al., 2013).
-
According to the Leukemia and Lymphoma Society, BPDCN constitutes less than 1% of all hematologic malignancies, resulting in an estimated 1,000 to 1,400 cases occurring annually in the US and Europe combined.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Blastic Plasmacytoid Dendritic Cell Neoplasm pipeline therapies. It also thoroughly assesses the Blastic Plasmacytoid Dendritic Cell Neoplasm market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Blastic Plasmacytoid Dendritic Cell Neoplasm drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Blastic Plasmacytoid Dendritic Cell Neoplasm epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Blastic Plasmacytoid Dendritic Cell Neoplasm epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Blastic Plasmacytoid Dendritic Cell Neoplasm Epidemiology, Segmented as –
-
Incident Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm in 7MM (2019–2032)
-
Stage-Specific Incident Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm in 7MM (2019–2032)
-
Gender-specific Incident Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm in 7MM (2019–2032)
-
Age-specific (Pediatric, Adult) cases of Blastic Plasmacytoid Dendritic Cell Neoplasm in 7MM (2019–2032)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Blastic Plasmacytoid Dendritic Cell Neoplasm market or expected to be launched during the study period. The analysis covers the Blastic Plasmacytoid Dendritic Cell Neoplasm market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Blastic Plasmacytoid Dendritic Cell Neoplasm drugs based on their sale and market share.
The report also covers the Blastic Plasmacytoid Dendritic Cell Neoplasm pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Blastic Plasmacytoid Dendritic Cell Neoplasm companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Blastic Plasmacytoid Dendritic Cell Neoplasm Market Will Evolve and Grow by 2032 @
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Therapeutics Analysis
The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world, and expected launch of emerging therapies during the forecast period. Companies across the globe are working towards the development of new treatment therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). There are currently many potential therapies for BPDCN in early-stage clinical trials that target CD123.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Companies Actively Working in the Therapeutics Market Include
-
Immunogen
-
Cellectis
-
MustangBio
-
Xencor
And many others
Emerging and Marketed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Therapies Covered in the Report Include:
-
IMGN632 (Immunogen)
-
UCART123 (Cellectis S.A)
-
MB 102 (MustangBio)
-
XmAb14045 (Xencor)
And Many More
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Blastic Plasmacytoid Dendritic Cell Neoplasm Competitive Intelligence Analysis
4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Overview at a Glance
5. Blastic Plasmacytoid Dendritic Cell Neoplasm Disease Background and Overview
6. Blastic Plasmacytoid Dendritic Cell Neoplasm Patient Journey
7. Blastic Plasmacytoid Dendritic Cell Neoplasm Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment Algorithm, Current Treatment, and Medical Practices
9. Blastic Plasmacytoid Dendritic Cell Neoplasm Unmet Needs
10. Key Endpoints of Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment
11. Blastic Plasmacytoid Dendritic Cell Neoplasm Marketed Therapies
12. Blastic Plasmacytoid Dendritic Cell Neoplasm Emerging Drugs and Latest Therapeutic Advances
13. Blastic Plasmacytoid Dendritic Cell Neoplasm Seven Major Market Analysis
14. Attribute Analysis
15. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Outlook (In US, EU5, and Japan)
16. Blastic Plasmacytoid Dendritic Cell Neoplasm Companies Active in the Market
17. Blastic Plasmacytoid Dendritic Cell Neoplasm Access and Reimbursement Overview
18. KOL Views on the Blastic Plasmacytoid Dendritic Cell Neoplasm Market
19. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Drivers
20. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Hay Fever Conjunctivitis Market
“Hay Fever Conjunctivitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hay Fever Conjunctivitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hay Fever Conjunctivitis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology